• MLN8237 (Alisertib): Applied Workflows for Cancer Biology Re

  2026-06-25

  MLN8237 (Alisertib) offers unmatched specificity for Aurora A kinase, unlocking new avenues in apoptosis induction, tumor growth suppression, and immune epigenetics. This article translates recent mechanistic insights and validated protocols into optimized experimental workflows, helping researchers maximize reproducibility and biological impact.

• ERAD-Hijacking Chimeras Enable Degradation of TM Proteins

  2026-06-25

  Song et al. present ERAD-engaging chimeras (ERADECs), a new small-molecule platform that hijacks the endoplasmic reticulum-associated degradation (ERAD) pathway to selectively degrade transmembrane proteins. This strategy addresses longstanding barriers in targeted protein degradation and offers new opportunities for membrane protein and immunology research.

• Calpeptin: Calpain Inhibitor Protocols in Pulmonary Fibrosis

  2026-06-24

  Calpeptin enables researchers to dissect calpain-driven pathways in fibrosis and inflammation with nanomolar precision. This guide translates cutting-edge reference data and peer-reviewed workflows into actionable protocols, troubleshooting, and optimization strategies for fibrosis research.

• SGK1 Inhibition in Translational Research: EMD638683 at the

  2026-06-23

  This thought-leadership article dissects the mechanistic and translational significance of SGK1 inhibition using EMD638683, spotlighting its role from endothelial biomechanics to tumor biology. Integrating recent breakthrough studies and practical workflow insights, it offers actionable guidance for researchers advancing cardiovascular and oncology research models.

• EdU Imaging Kits: Precision Cell Proliferation Assay Workflo

  2026-06-23

  EdU Imaging Kits (HF488) streamline DNA synthesis measurement with click chemistry, enabling sensitive, rapid cell proliferation assays without harsh denaturation. Optimized for both fluorescence microscopy and flow cytometry, these kits empower translational research in oncology and drug response evaluation.

• WEHI-539: Precision BCL-XL Inhibition for Apoptosis Research

  2026-06-22

  Explore how WEHI-539, a potent BCL-XL inhibitor, advances apoptosis research and cancer stem cell sensitization. This article offers a deeper analysis of assay design, selectivity, and the latest scientific findings for optimized experimental strategies.

• MLN8237 (Alisertib): Advanced Cancer Biology Applications &

  2026-06-22

  MLN8237 (Alisertib) delivers unmatched selectivity and potency for dissecting Aurora A kinase function in cancer biology, particularly in models where apoptosis induction and tumor growth inhibition are central outcomes. This guide details actionable protocols, troubleshooting strategies, and new insights from recent retinoblastoma studies, enabling researchers to optimize experimental success with confidence.

• BIBR 1532: Molecular Insights and Telomerase Inhibitor Impac

  2026-06-21

  Explore the scientific foundation and advanced research applications of BIBR 1532, a potent telomerase inhibitor. This article delivers a molecular-level analysis and protocol guidance, offering unique depth beyond standard assay workflows.

• ABT-737 in Precision Apoptosis: Mechanisms, Assay Impact, an

  2026-06-20

  Explore how ABT-737, a leading BCL-2 protein inhibitor, enables targeted apoptosis in cancer research. This article uniquely integrates mitochondrial signaling advances and assay strategy insights, providing actionable guidance beyond standard protocols.

• MCL-1’s Canonical Role in Breast Cancer Apoptosis Revealed

  2026-06-19

  This study rigorously demonstrates that breast cancer cell survival is fundamentally dependent on the anti-apoptotic function of MCL-1, not its non-canonical roles. The findings establish that targeting MCL-1’s canonical apoptosis pathway, rather than its other cellular functions, is critical for effective therapeutic intervention.

• Eltanexor (KPT-8602): Protocols and Innovations in Cancer Re

  2026-06-19

  Eltanexor (KPT-8602) stands out as a potent, oral XPO1 inhibitor with clinically validated activity against both hematological malignancies and solid tumors. This guide translates the latest mechanistic insights and published workflows into actionable protocols, troubleshooting tactics, and strategic optimization for advanced cancer modeling.

• Cisplatin (CDDP) Workflows: From DNA Crosslinking to Apoptos

  2026-06-18

  Cisplatin (CDDP) remains a linchpin in experimental cancer research, enabling robust apoptosis induction and chemoresistance modeling. This guide details state-of-the-art experimental workflows, translation of recent mechanistic insights, and actionable troubleshooting for reproducible results in both in vitro and in vivo systems.

• Strategic Mechanisms: AT-406 (SM-406) for Translational Canc

  2026-06-18

  This thought-leadership article integrates the latest atomic-level insights on death receptor signaling and caspase-8 regulation with actionable experimental and translational strategies for deploying AT-406 (SM-406) in cancer research. We explore mechanistic advances, experimental benchmarks, and clinical potential, contextualizing AT-406 as a pivotal tool for unlocking apoptosis pathway activation and chemosensitization in oncology models.

• ARCA Cy5 EGFP mRNA (5-moUTP): Precision for mRNA Delivery As

  2026-06-17

  Unlock direct, quantitative analysis of mRNA delivery and translation in mammalian cells using ARCA Cy5 EGFP mRNA (5-moUTP). This immune-evasive, dual-fluorescent mRNA streamlines localization and efficiency workflows—empowering advanced research in transfection and intracellular tracking.

• Antibody-Mediated SCUBE3 Targeting Suppresses Oncogenic Sign

  2026-06-17

  The referenced study identifies secretory SCUBE3 as a pivotal oncogenic and immunosuppressive driver in multiple cancer types. Targeting SCUBE3 with a neutralizing antibody disrupts tumor-promoting signaling and restores antitumor immunity, offering a promising new approach for pan-cancer therapy.

16723 records 1/1115 page Next 12345 下5页 Last page